Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

Success Metrics

Active Trials

0(0%)

Phase Distribution

Phase 1

33%

Phase 1/2

67%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

Phase 1/2Combined phases

2(66.7%)

Highest Phase Reached

Phase 1/2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Other(3)

Detailed Status

Suspended3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 1/2

Trials by Phase

Phase 11 (33.3%)

Phase 1/22 (66.7%)

Trials by Status

suspended3100%

Recent Activity

0 active trials

Showing 3 of 3

suspendedphase_1_2

Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders

NCT02946658

suspendedphase_1_2

Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells in Inflammatory Bowel Disease

NCT02952131

suspendedphase_1

Use of Autologous Stem/Stromal Cells In Chronic Lung Disorders: Obstructive (COPD) & Restrictive (RLD)

NCT03909750

Clinical Trials (3)

Showing 3 of 3 trials

NCT02946658Phase 1/2

Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders

Suspended

NCT02952131Phase 1/2

Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells in Inflammatory Bowel Disease

Suspended

NCT03909750Phase 1

Use of Autologous Stem/Stromal Cells In Chronic Lung Disorders: Obstructive (COPD) & Restrictive (RLD)

Suspended

All 3 trials loaded

Drug Details

Intervention Type: Procedure
Total Trials: 3